SEARCH

SEARCH BY CITATION

References

  • 1
    Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:353358.MEDLINE
  • 2
    Rimola A, Bory F, Planas R, Xaubet A, Bruguera M, Rodés J. Infecciones bacterianas agudas en la cirrosis hepática. Gastroenterol Hepatol 1981; 4:453458.
  • 3
    Andreu M, Barrufet P, Force L, Solá R, Verdaguer A, Panadés A, Arán R. Fiebre en el enfermo con cirrosis hepática: estudio prospectivo durante 6 meses. Med Clin 1985; 84:433436.
  • 4
    Clemente G, Barajas JM, Serrano MI, Pérez de Ayala MV, Menchén P, Senent MC, Castellanos D, et al. Infecciones bacterianas en la cirrosis hepática. Gastroenterol Hepatol 1986; 9:285290.
  • 5
    Suarez C, Pajares JM. Epidemiología de las infecciones en la cirrosis hepática. Rev Clin Esp 1981; 160:299303.MEDLINE
  • 6
    Palazón JM, Garcia A, Gómez A. Infecciones hospitalarias en pacientes con cirrosis hepática. Gastroenterol Hepatol 1984; 7:120122.
  • 7
    Levi D, Terg R, Podesta A, Abecasis R, de Gle G, Rafaelli C. Infecciones bacterianas en el paciente cirrótico. Gastroenterol Hepatol 1989; 12:384388.
  • 8
    Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, Tanikawa K. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol 1993; 88:20672071.MEDLINE
  • 9
    Deschenes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 1999; 94:21932197.MEDLINE
  • 10
    Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12:716724.MEDLINE
  • 11
    Rimola A, Garcia-Tsao G, Navasa M, Piddock LJV, Planas R, Bernard B, Inadomi JM, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32:142153.MEDLINE
  • 12
    Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38:340344.MEDLINE
  • 13
    Aparicio JR, Such J, Pascual S, Arroyo A, Plazas J, Girona E, Gutierrez A, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 1999; 31:277283.MEDLINE
  • 14
    Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122:595598.MEDLINE
  • 15
    Guarner C, Soriano G. Spontaneous bacterial peritonitis. Sem Liver Dis 1997; 17:203217.
  • 16
    Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95:13511355.MEDLINE
  • 17
    Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variants of spontaneous bacterial peritonitis. Hepatology 1984; 4:12091211.MEDLINE
  • 18
    Lo G-H, Lai K-H, Shen M-T, Chang C-F. A comparison of the incidence of transient bacteremia and infectious sequelae after sclerotherapy and rubber band ligation of bleeding esophageal varices. Gastrointest Endosc 1994; 40:675679.MEDLINE
  • 19
    Rimola A, Navasa M. Infections in liver disease. In: BircherJ, BenhamouJP, Mc IntyreN, RizzetoM, RodésJ, ed. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press 1999: 18611874.
  • 20
    Llach J, Elizalde JI, Bordas JM, Gines A, Almela M, Sans M, Mondelo F, et al. Prospective assessment of the risk of bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. Gastrointest Endosc 1999; 49:214217.MEDLINE
  • 21
    Hemderson DK. Bacteremia due to percutaneous intravascular devices. In: MandellGL, BennetJE, DolinR, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone 1995: 25872599.
  • 22
    Sobel JD, Kaye D. Urinary tract infections. In: MandellGL, BennetJE, DolinR, eds. Principles and Practice of Infectious Diseases. 4th Edition, New York: Churchill Livingstone, 1995: 662690.
  • 23
    Valenti WM, Chiarello LA. Overview of hospital infection control and nosocomial infections. In: ResseRE, DouglasJr.RG, eds. A Practical Approach to Infectious Diseases. Boston: Lippincott, 1986: 545555.
  • 24
    Young LS. Gram-negative sepsis. In: MandellGL, BennettJE, DolinR, eds. Principles and Practice of Infectious Diseases. 4th Edition, New York: Churchill Livingstone, 1995: 690705.
  • 25
    Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Ginès P, Rodés J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5:457462.MEDLINE
  • 26
    Gómez-Jimenez J, Ribera E, Gasser I, Artaza MA, Del Valle O, Pahissa A, Martinez-Vazquez JM. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrobial Agents Chemotheraphy 1993; 37:15871592.
  • 27
    National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial disk susceptibility test. Approved standard M2-A6. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
  • 28
    Castells A, Bruix J, Ayuso C, Bru C, Montanya X, Boix L, Rodes J. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22:410415.MEDLINE
  • 29
    Okuda K, Okuda H. Primary liver cell carcinoma. In: BircherJ, BenhamouJP, McIntyreN, RizzetoM, RodésJ, ed. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1999: 16791721.
  • 30
    Krajina A, Lojik M. TIPS- technique. In: HulekP, KrajinaA, ed. Current practice of TIPS. Progresstisk Hradec Kralove 2001: 56119.
  • 31
    Pinzello G, Simonetti RG, Craxi A, Di Piazza S, Spano C, Pagliaro L. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983; 3:545549.MEDLINE
  • 32
    Rimola A, Salmeron JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, Guarner C, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995; 21:674679.MEDLINE
  • 33
    Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996; 111:10111017.MEDLINE
  • 34
    Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R, Rimola A, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27:12271232.MEDLINE
  • 35
    Llovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, Menacho M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. J Hepatol 1997; 26:8895.MEDLINE
  • 36
    Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26:10661070.MEDLINE
  • 37
    Wyke RJ. Problems of bacterial infection in patients with liver disease. Gut 1987; 28:623641.MEDLINE
  • 38
    Rimola A. Infecciones bacterianas en la cirrosis hepática. MTA-Medicina Interna 1987; 5:161224.
  • 39
    Javaloyas M, Ariza J, Gudiol F. La bacteriemia en el paciente con cirrosis hepática. Análisis etiopatogénico y pronóstico de 92 casos. Med Clin 1984; 82:612616.
  • 40
    Diaz M, Fernández ML, Suarez C. Infecciones en la cirrosis hepática. Rev Clin Esp 1984; 172:241250.MEDLINE
  • 41
    González JF, Berenguer J, Muñoz P, Cuadros JA, Diaz M, Picazo J. Bacteriemia en pacientes con cirrosis hepática. Un estudio basado en 50 episodios. Gastroenterol Hepatol 1988; 11:3843.
  • 42
    Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29:430436.MEDLINE
  • 43
    Novella M, Solà R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997; 25:532536.MEDLINE
  • 44
    Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998; 59:5457.MEDLINE
  • 45
    Guarner C, Sola R, Soriano G, Andreu M, Novella MT, Vila MC, Sabat M, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999; 117:414419.MEDLINE
  • 46
    Ortiz J, Vila MC, Soriano G, Miñana J, Gana J, Mirelis B, Novella MT, et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients. Hepatology 1999; 29:10641069.MEDLINE
  • 47
    Castellote J, Xiol J, Rota Roca R, Fernández-Esparrach G. Spontaneous bacterial peritonitis and empyema by Escherichia coli resistant to norfloxacin in a patient on selective intestinal decontamination with norfloxacin. J Hepatol 1994; 20:436.MEDLINE
  • 48
    Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, Llovet T, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43:27362741.MEDLINE